all prices
| price | high | low | % | ||
|---|---|---|---|---|---|
| Dow Jones | 28014 | 28015 | 27957 | -0.04 % | |
| S&P500 | 3145 | 3146 | 3140 | -0.02 % | |
| Nasdaq 100 | 8395 | 8402 | 8379 | -0.08 % | |
| Euro Stoxx 50 | 3690 | 3690 | 3683 | -0.12 % | |
| FTSE 100 | 7228 | 7229 | 7214 | -0.07 % | |
| CAC40 | 5867 | 5868 | 5861 | -0.21 % | |
| DAX | 13174 | 13181 | 13149 | -0.03 % | |
| Hong Kong HSI | 26510 | 26626 | 26409 | -0.15 % | |
| Nikkei 225 | 23464 | 23544 | 23366 | -0.34 % |
Live stock markets prices
- 15 min
- 1H
- 4H
- Daily
| Dow Jones | 28014 | -0.04% |
|---|---|---|
| S&P500 | 3145 | -0.02% |
| Nasdaq 100 | 8394 | -0.08% |
| FTSE 100 | 7227 | -0.08% |
| CAC40 | 5867 | -0.21% |
|---|---|---|
| Nikkei 225 | 23469 | -0.32% |
| Euro Stoxx 50 | 3690 | -0.12% |
| DAX | 13173 | -0.03% |
Latest news
| CMR Surgical announces appointment of new Chief Executive Officer |
| Equinor ASA: Share buy-back |
| Share repurchase programme |
| Two more school districts in the US choose Anoto’s education platform KAIT to deliver AI-based individualized education |
| BGHL (EUR): NAV(s) |
| BGHL (GBP): NAV(s) |
| NOVEMBER 2019 TRAFFIC |
| Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion |
| Start of Day Message |
| Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA |
| ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix |
| Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak |
| Coop Pank results for November 2019 |
| Schibsted ASA (SCHA/SCHB) – Share buyback |
| Transactions of managers and of the persons closely related to the person discharging managerial responsibilities |
| ForFarmers N.V.: Update on share buy-back programme ForFarmers |
| MegumaGold Continues to Expand Land Position on Moose River Anticline |
| The Mystery of the Maldives, Unveiled |
| Landore Resources Limited Soil Sampling Program Establishes Significant Anomolous Gold Along Strike from the Bam Gold Project Junior Lake Property |
| U.S. Gold Corp. Announces Formation of Advisory Board |
CMR Surgical announces appointment of new Chief Executive Officer
CMR Surgical Limited
(âCMRâ or the âCompanyâ)
CMR Surgical announces appointment of new Chief Executive Officer
Cambridge, UK, 9 December 2019 â CMR Surgical (âCMRâ), the Company developing, manufacturing and marketing the next-generation surgical robotic system, Versius®, today announces the appointment of Per Vegard Nerseth as Chief Executive Officer, effective 1 January 2020. Martin Frost will remain Chief Executive Officer of CMR until this date before transitioning to a Non-Executive Director role at the Company.
Per Vegard Nerseth has more than 25 years of significant growth and business scaling experience in the field of robotics. He joins CMR from ABB, a world leading manufacturer of industrial robots and robot systems. For the last nine years he served as Senior Vice President and Managing Director of ABB Robotics, a multi-billion dollar business unit with more than 7,000 people in 53 countries. During his tenure ABB Robotics achieved double digit sales growth while making significant operational efficiencies. Prior to this Mr Nerseth established ABB Engineeringâs Robotics division in China, growing it to become the number one robotics business in China. Mr Nersethâs strong track record in scaling robotics will further support CMRâs accelerated growth trajectory as the Company works to bring minimal access surgery to everyone who needs it around the world.
Martin Frost co-founded CMR in 2014 and has been CEO since the Companyâs formation. During this time he has driven CMR to the point of commercialisation whilst attracting investment of a record-breaking £195 million in the Companyâs Series C financing round, which valued the business at more than £1 billion.
Martin Frost, CEO of CMR Surgical, said: âI am extremely proud of what we have achieved to date at CMR and I am delighted to be handing the CEO reins over to Per Vegard, who will lead the company to the next stages of its maturity. Per Vegard has strong experience in manufacturing and robotics at a multi-national level, which makes him the perfect candidate to take over. I look forward to continuing my involvement with the Company as a Non-Executive Director.â
Per Vegard Nerseth added: âI feel privileged to be joining this vibrant, rapidly growing, world-leading company at such an exciting stage in its development. I look forward to using my previous robotics and manufacturing experience to contribute to the future of CMR.â
Erik Langaker, Chairman of CMR Surgical, commented: âOn behalf of the Board and all shareholders, I would like to thank Martin for what he has achieved in building the business and leading what has been a rapidly growing team over the past five years. Martin has been instrumental to the success of CMR and our value based approach to healthcare and we are delighted to retain his expertise on the Board of Directors. I would also like to warmly welcome Per Vegard who will lead us through the next stage of CMRâs exciting journey. His long tenure with ABB, a world leader in designing, manufacturing and commercialising robotic solutions, will strongly complement our existing expertise to cement CMRâs position as a global player in surgical robotics.â
-Ends-
Contacts:
CMR Surgical
Patrick Pordage, Sarah GhabinaÂ
patrick.pordage@cmrsurgical.com / sarah.ghabina@cmrsurgical.com   Â
+44 (0)7864 922341 / +44(0)7749 432373Â
Consilium Strategic CommunicationsÂ
Mary-Jane Elliott, Angela Gray
CMR@consilium-comms.com
+44 (0)20 3709 5700Â
About CMR Surgical Limited
CMR Surgical is a British private limited company responsible for the development of the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.
The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.
Global annual revenues for robotic-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.
CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.
For further information, please visit www.cmrsurgical.com   Â
The Versius® Surgical Robotic System
Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® is able to move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.
Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.
Equinor ASA: Share buy-back
Equinor has on 6 December 2019 purchased 635,081 own shares at Oslo Stock Exchange at an average price of 167.9824 Norwegian kroner per share.
These share purchases form part of the first tranche of the company's share buy-back programme 2019-2022 announced on 5 September 2019. After this transaction Equinor owns a total of 21,976,392 own shares under the share buy-back programme.
For further information about the share buy-back programme, reference is made to the Oslo Stock Exchange notification published on 5 September 2019 (available from www.newsweb.no).
Share repurchase programme
The share buy-back programme runs as from 21 August 2019 and up to and including 31 March 2020. In this period, Jyske Bank will acquire shares with a value of up to DKK 1,000 million, cf. Corporate Announcement No. 47/2019 of 30 October 2019. The share buy-back programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called âMarket Abuse Regulationâ.
The following transactions have been made under the program:
| Â | Number of shares | Average purchase price | Transaction value in DKK |
| Accumulated, last announcement | 2,294,970 | 214.44 | 492,139,008 |
| 2 December 2019 | 27,444 | 224.92 | 6,172,715 |
| 3 December 2019 | 27,900 | 222.15 | 6,198,030 |
| 4 December 2019 | 27,555 | 222.31 | 6,125,763 |
| 5 December 2019 | 27,065 | 225.00 | 6,089,509 |
| 6 December 2019 | 27,354 | 224.61 | 6,144,045 |
| Accumulated under the programme | 2,432,288 | 214.97 | 522,869,070 |
With the transactions stated above, Jyske Bank now owns a total of 2,432,288 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.14% of the share capital.
In accordance with the EU Commission Regulation No. 596/2014, transactions related to the share buy-back programme are attached to this corporate announcement in detailed form.
                                                        Â
Yours faithfully,
Jyske Bank
Contact person: Simon Hagbart Madsen, tel. +45 89 89 71 85.
Attachment
Two more school districts in the US choose Anoto’s education platform KAIT to deliver AI-based individualized education
Stockholm, December 9, 2019 â Anoto Group AB (Anoto) today announces that it is expanding the student base on its education platform KAIT with one school district in West Virginia and another school district in Virginia, USA.
These two school districts have decided to start commercial pilots of the KAIT platform, and both districts will start to use KAIT from February 1, 2020. Combined, the two school districts are comprised of approximately 33,400 students in 45 schools.
âWith the addition of two more school districts in the US, KAIT has signed a grand total of 171 schools with approximately 111,000 students. As we are entering into the winter break, we are preparing for an updated version launch in early January 2020 and focusing on building a strong deployment and customer support organization. We will expand our network more aggressively next year and have recently added a new business development director in Europe and a new salesperson in the West Coast of the US,â said Joonhee Won, CEO of Anoto AB.Â
For further information, please contact:
Joonhee Won, CEO
For more information about Anoto, please visit www.anoto.com or email ir@anoto.com
Anoto Group AB (publ), Reg.No. 556532-3929, Flaggan 1165, SE-116 74 Stockholm
About Anoto Group
Anoto is a publicly held Swedish technology company known globally for innovation in the area of information-rich patterns and the optical recognition of those patterns. It is a leader in digital writing and drawing solutions, having historically used its proprietary technology to develop smartpens and the related software. These smartpens enrich the daily lives of millions of people around the world. Now Anoto is a cloud based software solution provider based on its patented dot pattern technology which provides a methodology for accumulating digital big data from analogue inputs. Anoto Cloud includes Anotoâs four solutions: KAIT â the worldâs first AI solution for offline education; ACE â Anotoâs new and improved enterprise forms solutions;Â aDNA â Anotoâs secure interactive marketing solution; and Dr. Watson â Anotoâs biometric authentication and security solution. Anoto is traded on the Small Cap list of Nasdaq Stockholm under ANOT.
BGHL (EUR): NAV(s)
                                     BOUSSARD & GAVAUDAN HOLDING LIMITED
Ordinary Shares
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
Close of business 06 Dec 2019.
Estimated NAV
| Â | Euro Shares | Sterling Shares |
| Estimated NAV | â¬Â 22.6651 | £ 20.5030 |
| Estimated MTD return | Â 0.09 % | Â 0.12 % |
| Estimated YTD return | Â 3.00 % | Â 4.37 % |
| Estimated ITD return | Â 126.65 % | Â 105.03 % |
NAV and returns are calculated net of management and performance fees
Market information
| Euro Shares | Amsterdam (AEX) | London (LSE) |
| Market Close | â¬Â 17.65 | N/A |
| Premium/discount to estimated NAV | Â -22.13 % | N/A |
| Â | Â | Â |
| Sterling Shares | Amsterdam (AEX) | London (LSE) |
| Market Close | N/A | GBX 1,560.00 |
| Premium/discount to estimated NAV | N/A | Â -23.91 % |
Transactions in own securities purchased into treasury
| Ordinary Shares | Euro Shares | Sterling Shares |
| Number of shares | N/A | N/A |
| Average Price | N/A | N/A |
| Range of Price | N/A | N/A |
          Â
                                         Â
| Liquidity Enhancement Agreement | Euro Shares | Sterling Shares |
| Number of shares | N/A | N/A |
| Average Price | N/A | N/A |
BGHL Capital
| BGHL Ordinary Shares | Euro Shares | Sterling Shares |
| Shares Outstanding | Â 15,104,678 | Â 398,542 |
| Held in treasury | N/A | N/A |
| Shares Issued | Â 15,104,678 | Â 398,542 |
Estimated BG Fund NAV
| Class B Euro Shares (estimated) | â¬Â 187.1401 |
The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.
For further information please contact:
Boussard & Gavaudan Investment Management, LLP.
Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com
The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.
This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.
Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.
You should always bear in mind that:
- all investment is subject to risk;
- results in the past are no guarantee of future results;
- the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and
- if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.
This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.
Attachment
BGHL (GBP): NAV(s)
                                     BOUSSARD & GAVAUDAN HOLDING LIMITED
Ordinary Shares
The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.
Close of business 06 Dec 2019.
Estimated NAV
| Â | Euro Shares | Sterling Shares |
| Estimated NAV | â¬Â 22.6651 | £ 20.5030 |
| Estimated MTD return | Â 0.09 % | Â 0.12 % |
| Estimated YTD return | Â 3.00 % | Â 4.37 % |
| Estimated ITD return | Â 126.65 % | Â 105.03 % |
NAV and returns are calculated net of management and performance fees
Market information
| Euro Shares | Amsterdam (AEX) | London (LSE) |
| Market Close | â¬Â 17.65 | N/A |
| Premium/discount to estimated NAV | Â -22.13 % | N/A |
| Â | Â | Â |
| Sterling Shares | Amsterdam (AEX) | London (LSE) |
| Market Close | N/A | GBX 1,560.00 |
| Premium/discount to estimated NAV | N/A | Â -23.91 % |
Transactions in own securities purchased into treasury
| Ordinary Shares | Euro Shares | Sterling Shares |
| Number of shares | N/A | N/A |
| Average Price | N/A | N/A |
| Range of Price | N/A | N/A |
          Â
                                         Â
| Liquidity Enhancement Agreement | Euro Shares | Sterling Shares |
| Number of shares | N/A | N/A |
| Average Price | N/A | N/A |
BGHL Capital
| BGHL Ordinary Shares | Euro Shares | Sterling Shares |
| Shares Outstanding | Â 15,104,678 | Â 398,542 |
| Held in treasury | N/A | N/A |
| Shares Issued | Â 15,104,678 | Â 398,542 |
Estimated BG Fund NAV
| Class B Euro Shares (estimated) | â¬Â 187.1401 |
The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.
For further information please contact:
Boussard & Gavaudan Investment Management, LLP.
Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com
The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.
This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.
Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.
You should always bear in mind that:
- all investment is subject to risk;
- results in the past are no guarantee of future results;
- the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and
- if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.
This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.
Attachment
NOVEMBER 2019 TRAFFIC
 Â
9 December 2019
NOVEMBER 2019 TRAFFIC
Group passenger activity: number of passengers +1.3%, traffic +3.6%, load factor
+1.1pt
          Â
Traffic highlights
| Passenger network activity (Air France and KLM) | Capacity (ASK, %ch.) | Traffic (RPK, %ch.) | Load Factor  (%) | Change (pts) |
| Long-haul | + 4.1% | + 4.8% | 87.6% | + 0.6 |
| North America | + 3.5% | + 5.2% | 89.2% | + 1.5 |
| Latin America | + 3.8% | + 4.1% | 85.2% | + 0.3 |
| Asia | + 4.8% | + 4.9% | 90.2% | + 0.1 |
| Africa / Middle East | + 1.6% | + 2.6% | 83.0% | + 0.8 |
| Caribbean / Indian Ocean | + 7.6% | + 7.4% | 88.2% |  - 0.2 |
| Short and Medium-haul | - 3.0% | + 0.9% | 84.3% | + 3.2 |
| Total | + 2.7% | + 4.1% | 87.0% | + 1.1 |
4Â Â 6.8 million passengers, +1.5%
| Transavia activity | Capacity (ASK, %ch.) | Traffic (RPK, %ch.) | Load Factor  (%) | Change (pts) |
| Â Total | - 3.1% | - 1.6% | 92.6% | + 1.4 |
4Â Â 0.9 million passengers, -0.5%
| Total group passenger activity (Air France, KLM and Transavia) | Capacity (ASK, %ch.) | Traffic (RPK, %ch.) | Load Factor  (%) | Change (pts) |
| Total | + 2.3% | + 3.6% | 87.4% | + 1.1 |
4Â Â 7.7 million passengers, +1.3%
| Cargo activity | Capacity (ATK, %ch.) | Traffic (RTK, %ch.) | Load Factor  (%) | Change (pts) |
| Total | + 2.5% | - 3.4% | 61.4% | Â - 3.7 |
Agenda
9th January: December 2019 traffic
20th of February 2020: Full Year 2019 results
Investor relations                                                                                      Press
Olivier Gall                                         Wouter van Beek                                                       Â
+33 1 49 89 52 59 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â +33 1 49 89 52 60Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â +33 1 41 56 56 00
olgall@airfranceklm.com                     wouter-van.beek@airfranceklm.com
Website: www.airfranceklm.com
STATISTICS
Passenger network activity*
| Â | Â | November | Â | Â | Year to date | ||
| Total Passenger network* | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Passengers carried (â000s) | 6,844 | 6,741 | 1.5% | Â | 80,746 | 78,833 | 2.4% |
| Revenue pax-kilometers (m RPK) | 20,896 | 20,077 | 4.1% | Â | 241,872 | 234,619 | 3.1% |
| Available seat-kilometers (m ASK) | 24,016 | 23,379 | 2.7% | Â | 274,505 | 267,854 | 2.5% |
| Load factor (%) | 87.0% | 85.9% | 1.1 | Â | 88.1% | 87.6% | 0.5 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Long-haul | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 2,262 | 2,158 | 4.8% | Â | 25,932 | 25,161 | 3.1% |
| Revenue pax-kilometers (m RPK) | 17,144 | 16,359 | 4.8% | Â | 195,703 | 189,812 | 3.1% |
| Available seat-kilometers (m ASK) | 19,563 | 18,790 | 4.1% | Â | 220,141 | 214,246 | 2.8% |
| Load factor (%) | 87.6% | 87.1% | 0.6 | Â | 88.9% | 88.6% | 0.3 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| North America | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 631 | 599 | 5.3% | Â | 8,089 | 7,638 | 5.9% |
| Revenue pax-kilometers (m RPK) | 4,499 | 4,276 | 5.2% | Â | 57,486 | 54,461 | 5.6% |
| Available seat-kilometers (m ASK) | 5,042 | 4,871 | 3.5% | Â | 64,319 | 61,121 | 5.2% |
| Load factor (%) | 89.2% | 87.8% | 1.5 | Â | 89.4% | 89.1% | 0.3 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Latin America | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 304 | 290 | 4.7% | Â | 3,338 | 3,135 | 6.5% |
| Revenue pax-kilometers (m RPK) | 2,847 | 2,735 | 4.1% | Â | 31,691 | 30,006 | 5.6% |
| Available seat-kilometers (m ASK) | 3,341 | 3,220 | 3.8% | Â | 35,618 | 33,370 | 6.7% |
| Load factor (%) | 85.2% | 84.9% | 0.3 | Â | 89.0% | 89.9% | (0.9) |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Asia / Pacific | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 559 | 531 | 5.3% | Â | 6,093 | 5,891 | 3.4% |
| Revenue pax-kilometers (m RPK) | 4,843 | 4,618 | 4.9% | Â | 53,179 | 51,618 | 3.0% |
| Available seat-kilometers (m ASK) | 5,372 | 5,128 | 4.8% | Â | 58,591 | 56,891 | 3.0% |
| Load factor (%) | 90.2% | 90.1% | 0.1 | Â | 90.8% | 90.7% | 0.0 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Africa / Middle East | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 459 | 453 | 1.5% | Â | 5,005 | 5,101 | (1.9%) |
| Revenue pax-kilometers (m RPK) | 2,658 | 2,591 | 2.6% | Â | 28,395 | 28,832 | (1.5%) |
| Available seat-kilometers (m ASK) | 3,204 | 3,152 | 1.6% | Â | 33,656 | 34,546 | (2.6%) |
| Load factor (%) | 83.0% | 82.2% | 0.8 | Â | 84.4% | 83.5% | 0.9 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Caribbean / Indian Ocean | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 309 | 286 | 8.3% | Â | 3,407 | 3,397 | 0.3% |
| Revenue pax-kilometers (m RPK) | 2,297 | 2,138 | 7.4% | Â | 24,952 | 24,895 | 0.2% |
| Available seat-kilometers (m ASK) | 2,604 | 2,419 | 7.6% | Â | 27,956 | 28,318 | (1.3%) |
| Load factor (%) | 88.2% | 88.4% | (0.2) | Â | 89.3% | 87.9% | 1.3 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Short and Medium-haul | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 4,582 | 4,583 | (0.0%) | Â | 54,814 | 53,671 | 2.1% |
| Revenue pax-kilometers (m RPK) | 3,752 | 3,718 | 0.9% | Â | 46,170 | 44,806 | 3.0% |
| Available seat-kilometers (m ASK) | 4,453 | 4,588 | (3.0%) | Â | 54,364 | 53,608 | 1.4% |
| Load factor (%) | 84.3% | 81.0% | 3.2 | Â | 84.9% | 83.6% | 1.3 |
* Air France and KLM
Transavia activity       Â
| Â | Â | November | Â | Â | Year to date | ||
| Transavia | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Passengers carried (â000s) | 870 | 875 | (0.5%) | Â | 15,713 | 14,933 | 5.2% |
| Revenue pax-kilometers (m RPK) | 1,646 | 1,673 | (1.6%) | Â | 28,669 | 26,694 | 7.4% |
| Available seat-kilometers (m ASK) | 1,777 | 1,834 | (3.1%) | Â | 31,031 | 28,931 | 7.3% |
| Load factor (%) | 92.6% | 91.2% | 1.4 | Â | 92.4% | 92.3% | 0.1 |
Total group passenger activity**
| Â | Â | November | Â | Â | Year to date | ||
| Total group** | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Passengers carried (â000s) | 7,714 | 7,616 | 1.3% | Â | 96,459 | 93,765 | 2.9% |
| Revenue pax-kilometers (m RPK) | 22,542 | 21,749 | 3.6% | Â | 270,541 | 261,313 | 3.5% |
| Available seat-kilometers (m ASK) | 25,793 | 25,213 | 2.3% | Â | 305,536 | 296,786 | 2.9% |
| Load factor (%) | 87.4% | 86.3% | 1.1 | Â | 88.5% | 88.0% | 0.5 |
** Air France, KLM and Transavia
Cargo activity
| Â | Â | November | Â | Â | Year to date | ||
| Total Group | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Revenue tonne-km (m RTK) | 739 | 765 | (3.4%) | Â | 7,733 | 7,891 | (2.0%) |
| Available tonne-km (m ATK) | 1,202 | 1,173 | 2.5% | Â | 13,354 | 13,156 | 1.5% |
| Load factor (%) | 61.4% | 65.2% | (3.7) | Â | 57.9% | 60.0% | (2.1) |
Air France activity
| Â | Â | November | Â | Â | Year to date | ||
| Total Passenger network activity | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Passengers carried (â000s) | 4,099 | 4,050 | 1.2% | Â | 48,425 | 47,350 | 2.3% |
| Revenue pax-kilometers (m RPK) | 12,109 | 11,564 | 4.7% | Â | 141,387 | 135,672 | 4.2% |
| Available seat-kilometers (m ASK) | 14,076 | 13,672 | 3.0% | Â | 162,247 | 157,075 | 3.3% |
| Load factor (%) | 86.0% | 84.6% | 1.4 | Â | 87.1% | 86.4% | 0.8 |
| Long-haul | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 1,325 | 1,259 | 5.2% | Â | 15,432 | 14,791 | 4.3% |
| Revenue pax-kilometers (m RPK) | 9,863 | 9,334 | 5.7% | Â | 113,781 | 108,847 | 4.5% |
| Available seat-kilometers (m ASK) | 11,358 | 10,834 | 4.8% | Â | 129,084 | 124,230 | 3.9% |
| Load factor (%) | 86.8% | 86.2% | 0.7 | Â | 88.1% | 87.6% | 0.5 |
| Short and Medium-haul | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 2,774 | 2,791 | (0.6%) | Â | 32,993 | 32,559 | 1.3% |
| Revenue pax-kilometers (m RPK) | 2,247 | 2,229 | 0.8% | Â | 27,606 | 26,825 | 2.9% |
| Available seat-kilometers (m ASK) | 2,719 | 2,839 | (4.2%) | Â | 33,163 | 32,845 | 1.0% |
| Load factor (%) | 82.6% | 78.5% | 4.1 | Â | 83.2% | 81.7% | 1.6 |
| Â | Â | November | Â | Â | Year to date | ||
| Cargo activity | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Revenue tonne-km (m RTK) | 328 | 346 | (5.1%) | Â | 3,446 | 3,459 | (0.4%) |
| Available tonne-km (m ATK) | 597 | 575 | 3.8% | Â | 6,709 | 6,528 | 2.8% |
| Load factor (%) | 54.9% | 60.1% | (5.2) | Â | 51.4% | 53.0% | (1.6) |
KLM activity
| Â | Â | November | Â | Â | Year to date | ||
| Total Passenger network activity | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Passengers carried (â000s) | 2,745 | 2,691 | 2.0% | Â | 32,321 | 31,482 | 2.7% |
| Revenue pax-kilometers (m RPK) | 8,786 | 8,513 | 3.2% | Â | 100,486 | 98,947 | 1.6% |
| Available seat-kilometers (m ASK) | 9,939 | 9,707 | 2.4% | Â | 112,257 | 110,779 | 1.3% |
| Load factor (%) | 88.4% | 87.7% | 0.7 | Â | 89.5% | 89.3% | 0.2 |
| Long-haul | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 937 | 898 | 4.3% | Â | 10,500 | 10,370 | 1.3% |
| Revenue pax-kilometers (m RPK) | 7,281 | 7,024 | 3.7% | Â | 81,921 | 80,966 | 1.2% |
| Available seat-kilometers (m ASK) | 8,205 | 7,957 | 3.1% | Â | 91,056 | 90,016 | 1.2% |
| Load factor (%) | 88.7% | 88.3% | 0.5 | Â | 90.0% | 89.9% | 0.0 |
| Short and Medium-haul | Â | Â | Â | Â | Â | Â | Â |
| Passengers carried (â000s) | 1,808 | 1,793 | 0.8% | Â | 21,821 | 21,112 | 3.4% |
| Revenue pax-kilometers (m RPK) | 1,505 | 1,488 | 1.1% | Â | 18,564 | 17,981 | 3.2% |
| Available seat-kilometers (m ASK) | 1,734 | 1,750 | (0.9%) | Â | 21,201 | 20,763 | 2.1% |
| Load factor (%) | 86.8% | 85.1% | 1.7 | Â | 87.6% | 86.6% | 1.0 |
| Â | Â | November | Â | Â | Year to date | ||
| Cargo activity | 2019 | 2018 | Variation | Â | 2019 | 2018 | Variation |
| Revenue tonne-km (m RTK) | 411 | 419 | (2.0%) | Â | 4,287 | 4,432 | (3.3%) |
| Available tonne-km (m ATK) | 605 | 598 | 1.2% | Â | 6,645 | 6,628 | 0.3% |
| Load factor (%) | 67.9% | 70.0% | (2.2) | Â | 64.5% | 66.9% | (2.4) |
Attachment
Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
| Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion Â
PARIS and San Diego, California â December 9, 2019 â Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis). The transaction was unanimously approved by both the Sanofi and Synthorx Boards of Directors.  âThis acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation, as you will hear at our Capital Markets Day tomorrow, December 10. Additionally, it is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations," says Paul Hudson, Chief Executive Officer, Sanofi.  âSynthorxâs exceptionally novel discovery platform has already produced a molecule that has the potential to become a foundation of the next generation of immuno-oncology combination therapies. By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with our current oncology medicines and our emerging pipeline of immuno-modulatory agents for treating cancer. Moreover, Synthorxâs pipeline of engineered lymphokines has great promise not only for oncology but also for addressing many autoimmune and inflammatory diseases. â says John Reed, M.D., Ph.D., Global Head of Research & Development at Sanofi.  âWe are grateful that Sanofi has acknowledged the value of our Expanded Genetic Alphabet platform and the potential of our pipeline of optimized therapeutics for cancer and autoimmune disorders,â says Laura Shawver, Ph.D., President and Chief Executive Officer, Synthorx. âImportantly, Sanofi has a portfolio of therapeutics that holds incredible promise for combining with our cytokine Synthorins to benefit patients around the world. I want to thank our employees and the Sanofi organization for their relentless efforts on behalf of patients.â  Enhancing Sanofiâs Immuno-Oncology Franchise  Synthorxâs lead immuno-oncology product candidate, THOR-707, a variant of interleukin-2 (IL-2), is in clinical development in multiple solid tumor types as a single agent and in combination with immune checkpoint inhibitors. It has the potential to become the best-in-class IL-2 therapeutic for the treatment of solid tumors and demonstrate improved pharmacology, less frequent dosing, and therapeutic superiority when compared to other IL-2 compounds.  The addition of THOR-707 and Synthorxâs other earlier-stage cytokine programs to Sanofiâs pipeline will enhance Sanofiâs position in oncology, and in immuno-oncology. We expect IL-2 to become a foundation of future IO-IO combinations as well as offering multiple combination opportunities with Sanofiâs clinical and pre-clinical oncology assets, including with PD-1, CD-38, and molecules that modulate effector T-cells and natural killer cells.  Synergistic with Sanofiâs existing platforms  Synthorxâs Expanded Genetic Alphabet platform is expected to be a source for developing a differentiated therapeutic pipeline. Alone and in combination with other existing Sanofi platforms, including the Nanobody® technology, it will enable the company to develop a wide range of novel biologics, including drug conjugates, protein fusions, and multi-specific biologics, with applications beyond oncology and extending to other therapeutic areas.  Transaction Terms  Under the terms of the merger agreement, Sanofi will commence a cash tender offer to acquire all of the outstanding shares of Synthorx common stock for $68 per share in cash for a total enterprise value of approximately $2.35 billion. The $68 per share acquisition price represents a 172% premium to Synthorxâs closing price on December 6, 2019.  The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Synthorx common stock, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of Sanofi will merge with Synthorx and the outstanding Synthorx shares not tendered in the tender offer will be converted into the right to receive the same $68 per share in cash paid in the tender offer. The tender offer is expected to commence in December 2019. Sanofi plans to finance the transaction with cash on hand. Subject to the satisfaction or waiver of customary closing conditions, Sanofi expects to complete the acquisition in the first quarter of 2020.  Morgan Stanley & Co. is acting as financial advisor to Sanofi and Weil, Gotshal & Manges LLP is acting as its legal counsel. Centerview Partners LLC is acting as exclusive financial advisor to Synthorx and Cooley LLP is acting as its legal counsel.  About Synthorx Synthorx, Inc. is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorxâs proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The companyâs lead immuno-oncology (IO) product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries by Dr. Floyd Romesberg and The Scripps Research Institute. Synthorx is headquartered in La Jolla, Calif. For more information, visit www.Synthorx.com.  | |
|  About Sanofi  Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.  With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.  Sanofi, Empowering Life  | |
| Media Relations Contact Ashleigh Koss Tel.: +1 908 205 2572 ashleigh.koss@sanofi.com  Synthorx Media Relations Lauren Fish Canale Communications Tel.:619-849-5386 lauren@canalecomm.com    |  Sanofi Investor Relations George Grofik Tel.: +33 (0)1 53 77 45 45 ir@Sanofi.com  Synthorx Investor Relations Enoch Kariuki, Pharm.D. Tel.: +1 858-750-4750 ekariuki@Synthorx.com  Christina Tartaglia Stern IR, Inc. Tel.: +1 212-362-1200 christina.tartaglia@sternir.com  |
|  Sanofi and Synthorx Forward-Looking Statements This communication contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words âexpectsâ, âanticipatesâ, âbelievesâ, âintendsâ, âestimatesâ, âplansâ, âwill beâ and similar expressions. Although Sanofiâs and Synthorxâs management each believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi and Synthorx, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Sanofiâs and Synthorxâs ability to complete the acquisition on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals, the possibility that competing offers will be made, other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed acquisition, disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers, suppliers or patient groups, and the possibility that, if the combined company does not achieve the perceived benefits of the proposed acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Sanofiâs shares could decline, as well as other risks related Sanofiâs and Synthorxâs respective businesses, including the ability to grow sales and revenues from existing products and to develop, commercialize or market new products, competition, including potential generic competition, the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the FDA or the EMA, including decisions of such authorities regarding whether and when to approve any drug, device or biological application that may be filed for any product candidates as well as decisions regarding labelling and other matters that could affect the availability or commercial potential of any product candidates, the absence of a guarantee that any product candidates, if approved, will be commercially successful, risks associated with intellectual property, including the ability to protect intellectual property and defend patents, future litigation, the future approval and commercial success of therapeutic alternatives, and volatile economic conditions. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on companiesâ consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in the public filings with the U.S. Securities and Exchange Commission (the âSECâ) and the AMF made by Sanofi, including those listed under âRisk Factorsâ and âCautionary Statement Regarding Forward-Looking Statementsâ in Sanofiâs annual report on Form 20-F for the year ended December 31, 2018, and the current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K filed by Synthorx with the SEC. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Sanofi and Synthorx do not undertake any obligation to update or revise any forward-looking information or statements  Additional Information for US shareholders The tender offer for the outstanding shares of Synthorx common stock referenced in this press release has not yet commenced. This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Sanofi and its acquisition subsidiary will file with the SEC, upon the commencement of the tender offer. At the time the tender offer is commenced, Sanofi and its acquisition subsidiary will file a tender offer statement on Schedule TO and thereafter Synthorx will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. SYNTHORX STOCKHOLDERS ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF SYNTHORX SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of Synthorx stock at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SECâs website at www.sec.gov. Additional copies may be obtained for free by contacting Sanofi or Synthorx. Copies of the documents filed with the SEC by Synthorx will be available free of charge on Synthorxâs internet website at https://ir.synthorx.com or by contacting Synthorxâs Investor Relations Department at ir@synthorx.com. Copies of the documents filed with the SEC by Sanofi will be available free of charge on Sanofiâs internet website at https://en.sanofi.com/investors or by contacting Sanofiâs Investor Relations Department at ir@sanofi.com.  In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Sanofi files annual and special reports and other information with the SEC and Synthorx files annual, quarterly and special reports and other information with the SEC. You may read and copy any reports or other information filed by Sanofi and Synthorx at the SEC public reference room at 100 F. Street, N.E., Washington D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room. Sanofiâs and Synthorxâs filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov   | |
Â
Attachment
Start of Day Message
LONDON, 09 Dec. 2019 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire.
GlobeNewswire is operated by West Corporation and is designated by the FCA as an approved primary information provider.
Disclaimer
The content and accuracy of all information distributed through GlobeNewswire is wholly the responsibility of the originator. West Corporation accepts no liability for any losses arising from reliance by any person upon the content of any announcement.
If you have any questions about this message, please Contact Us.
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
Regulated information
Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings
Gosselies, Belgium, 9 December 2019, 7am CET â BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapies to address high unmet medical needs in orthopaedics and bone diseases, today announces that it has received a transparency notification dated 3 December 2019 indicating that the shareholdings held by S.R.I.W. SA (Société Régional dâInvestissement de Wallonie) and its subsidiary Sofipôle SA (Société Wallonne pour le Financement des Infrastructures des Pôles de Compétitivité) have passively crossed the threshold of 10% as a result of the issuance of new shares on 14 November 2019 following the conversion of convertible bonds issued on the private placement on 7 March 2018.
The notification dated 3Â December 2019 contains the following information:
- Reason for the notification: Passive crossing of a threshold
- Notification by: A parent undertaking or a controlling person
- Persons subject to the notification requirement: S.R.I.W. SA & Sofipôle SA
- Transaction date: 14Â November 2019
- Threshold that is crossed: 10%
- Denominator: 10,620,686
- Notified details:
| Voting rights | Previous notification | After the transaction | |
| Holders of voting rights | # of voting rights | # of voting rights | % of voting rights |
| S.R.I.W. SA | 344,530 | 344,530 | 3.24% |
| Sofipôle SA | 703,823 | 703,823 | 6.63% |
| Total voting rights held by S.R.I.W and Sofipôle | 1,048,353 | 1,048,353 | 9.87% |
·Full chain of controlled undertakings through which the holding is effectively held: The Walloon Region holds 99.43% of S.R.I.W. SA which controls 60% of the shares of Sofipôle SA.
The notification can be consulted on the website of Bone Therapeutics, under the heading âShareholder informationâ.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.
Bone Therapeuticsâ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.
The Companyâs ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase IIb clinical development for the treatment of difficult-to-heal fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an off-the-shelf protein solution, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.
Bone Therapeuticsâ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.
Contacts
Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0) 71 12 10 00
investorrelations@bonetherapeutics.com
International Media Enquiries:
Consilium Strategic Communications
Marieke Vermeersch
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com
For French Media and Investor Enquiries:
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
- Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints
- 93.9% responder rate for 200 mg with ABT (p < 0.001)
- 56.7% responder rate for 100 mg without ABT (p < 0.001)
- Both doses achieved important clinically relevant secondary endpoints including amenorrhea (p < 0.001), reduction in pain (p < 0.001), improvement in quality of life (p < 0.001) and improvement in hemoglobin levels (p < 0.002)
            Â
            Â
GENEVA, Switzerland and BOSTON, MA (December 9, 2019) â ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womenâs reproductive health, today reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids.
The PRIMROSE 2 trial enrolled 535 women with HMB due to uterine fibroids. The trial was conducted in Europe and the US and evaluated the efficacy and safety of once daily oral linzagolix, including 100 mg and 200 mg doses, both with and without hormonal add-back therapy (ABT). The primary efficacy endpoint was the reduction in HMB. Responders were defined as patients with menstrual blood loss volume of ⤠80 mL and ⥠50% reduction from baseline in menstrual blood loss volume at 24 weeks, measured using the alkaline hematin method. Bone mineral density (BMD) was assessed centrally using Dual Energy X-ray Absorptiometry (DEXA) scan at baseline and 24 weeks.
The responder rate was 93.9% (p < 0.001) for women receiving 200 mg with ABT and 56.7% for women receiving 100 mg without ABT (p < 0.001), compared to 29.4% in the placebo group. Both doses achieved significant rates of amenorrhea (p < 0.001), reduction in pain (p < 0.001), and improvement in quality of life (p < 0.001). Additionally, significant improvement (p < 0.001) in hemoglobin levels, a reduction in number of days of bleeding and reduction in uterine volume were observed. Furthermore, a significant reduction in fibroid volume was also observed for the 200 mg dose with ABT (p < 0.008).
The overall safety profile was in line with expectations and confirmed that linzagolix was well-tolerated. The most frequently observed adverse events (occurring in > 5% of patients) were headache, hot flushes, and anemia. Mean percentage change from baseline in BMD was consistent with previous clinical data.
âWe are extremely pleased with these results for linzagolix in our first phase 3 study in women with heavy menstrual bleeding due to uterine fibroids,â said Dr. Ernest Loumaye, ObsEva CEO and Co-Founder. âThe excellent responder rates for the 200 mg with ABT and the 100 mg dose without ABT strongly support our dual strategy of development for linzagolix. The full suppression 200 mg dose with ABT achieved a potentially best in class, 94% responder rate. Importantly, the 100 mg dose without ABT with over 50% of women responding, provides a meaningful option for the significant proportion of women who cannot or do not want to take exogenous hormones. We look forward to the results from our second pivotal study, PRIMROSE 1 conducted in the US, in Q2 2020. Assuming positive results, we expect that it would lead to a Marketing Authorization Application submission with the European Medicines Agency by year-end 2020 and a New Drug Application submission with the U.S. Food and Drug Administration by Q1 2021.â
Dr. Hugh Taylor, Professor and Chair of Obstetrics and Gynecology at Yale University, said, âWomen with uterine fibroids need non-surgical alternatives to reduce the often unbearable effects of heavy menstrual bleeding. The prospects for a medical treatment with multiple dosing options would address a need for this diverse population of women. I am particularly impressed with the 94% responder rate and 80% amenorrhea rate that linzagolix has shown.â
Conference Call and Webcast Today
ObsEva will host a conference call and audio webcast today beginning at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to discuss Phase 3 PRIMROSE 2 trial results of linzagolix. Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers and referring to conference ID 1764134. A live or archived webcast of the conference call can be accessed under the âInvestorsâ section of ObsEvaâs website www.ObsEva.com.
About Linzagolix
Linzagolix (previously known as OBE2109) is a novel, oral, once daily, GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product.
About PRIMROSE 2
PRIMROSE 2 is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of two dosing regimens of linzagolix, 100mg and 200mg once daily, alone and in combination with hormonal ABT for the treatment of HMB associated with uterine fibroids. Women participating in the trial did not receive Vitamin D or calcium supplementation. The trial was conducted in Europe and the US and enrolled 535 women for a treatment period of 12 months.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womenâs reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol âOBSNâ. For more information, please visit www.ObsEva.com.
About Kissei
Kissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and Unmet Medical Needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia which is sold worldwide through its licensees. KLH-2109/OBE2109 is a new chemical entity discovered by Kissei R&D.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEvaâs current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEvaâs product candidates, the timing of data from clinical trials, ObsEvaâs expectations regarding its plan to submit its  Marketing Authorization Application with the European Medicines Agency and New Drug Application with the FDA, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEvaâs reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEvaâs Annual Report on Form 20-F for the year ended December 31, 2018, the Risk Factors filed as Exhibit 99.1 to ObsEvaâs Form 6-K filed on August 7, 2019, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEvaâs website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile
Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4017 Office
+1 646 537 5649 Mobile
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Attachment
Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak
COPENHAGEN, Denmark, December 9, 2019 â Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced, that its partner Janssen Pharmaceutical Companies of Johnson & Johnson will provide up to 200,000 regimens of its investigational Ebola vaccine to the Republic of Rwanda to support a new immunization program led by the Rwanda government. The vaccine regimen, which consists of the MVA-BN® Filo vaccine from Bavarian Nordic and the Ad26.ZEBOV vaccine from Janssen, will help protect the citizens of Rwanda from the current Ebola outbreak in the neighboring country, the Democratic Republic of Congo (DRC).
The World Health Organization (WHO) has declared the Ebola outbreak in the DRC a Public Health Emergency of International Concern (PHEIC). More than 3,300 cases, including more than 2,200 deaths, have been reported to date, making the outbreak second only to the 2014-2016 West Africa epidemic. In October, Johnson & Johnson announced a donation of up to 500,000 regimens of the investigational vaccine to be part of an expanded response in DRC.
In July 2019, the fear of further spread of Ebola to Rwanda heightened due to two cases of the disease being reported in the DRC city of Goma, a major trading hub located near the Rwandan border. Because a significant number of Rwandan citizens cross the border to the DRC on a regular basis as part of their everyday life, the Rwanda Ministry of Health has established a large-scale vaccination campaign involving approximately 200,000 Rwandan citizens from age two and older in the regions bordering the DRC judged to be at risk. The program is initiated with the objective of creating a protective barrier to prevent Ebola from impacting the Rwandan citizens and from spreading further.
âWe applaud the decision by the Rwandan authorities to introduce the Janssen/Bavarian Nordic vaccine to help prevent the Ebola virus from spreading in to the country, and we are proud to be a contributing partner in the development of a vaccine which is now actively being used in large-scale efforts to contain the virus in both the DRC, Uganda and Rwanda,â said Paul Chaplin, President and CEO of Bavarian Nordic.
Background
In 2014, in response to the Ebola epidemic in West Africa, Johnson & Johnson accelerated the development of a preventive Ebola vaccine regimen with multiple global partners across the U.S., Europe and Africa. The regimen (Ad26.ZEBOV, MVA-BN-Filo) uses a combination of two vaccines based on AdVac® technology from Janssen, and MVA-BN® technology from Bavarian Nordic. The first dose primes the immune system, and the second aims to enhance the duration of the immune response. These vaccines both use a viral vector approach, where a virus is genetically modified so that it cannot replicate but is used to safely express key proteins of the target virus, in this case Ebola virus. To date, nearly 8,000 individuals across the U.S., Europe and Africa have participated in multiple Janssen-sponsored and partner-led clinical studies. The available clinical data suggest that the vaccine regimen has a favorable safety profile, is well tolerated, and induces robust and durable immune responses against the Ebola virus Zaire strain â the cause of the DRC outbreak. In November 2019, Janssen submitted Marketing Authorisation Applications to the European Medicines Agency seeking licensure for the investigational Ebola vaccine regimen.
Under the agreement with Janssen in 2014, Bavarian Nordic licensed MVA-BN Filo to Janssen and manufactured a significant amount of vaccines for the stockpile, which is now being deployed in the DRC and Rwanda.
The vaccine regimen was developed in a collaborative research program with the NIH and received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases, part of NIH, under Contract Numbers HHSN272200800056C, and HHSN272201000006I and HHSN272201200003I, respectively. Further funding for the Ebola vaccine regimen has been provided in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, BARDA under Contract Numbers HHSO100201700013C and HHSO100201500008C.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to unlock the power of the immune system to improve public health with a focus on high unmet medical needs. In addition to our long-standing collaboration with the U.S. government on the development and supply of medical countermeasures, including the only FDA-approved, non-replicating smallpox vaccine, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable benefit-risk profile. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Graham Morrell
Paddock Circle Advisors (US)
graham@paddockcircle.com
Tel: +1 781 686 9600
Press Release
Attachment
Coop Pank results for November 2019
Company Announcement
9 December 2019
 Coop Pankâs financial results in November 2019:
- The bankâs customer base increased by a record 3,600, reaching 61,900 by the end of the month.
- In the same period, the bankâs loan portfolio increased by EUR 21 million, having reached EUR 447 million. Business loans showed the highest growth, while all other financing business lines contributed to the growth as well.
- The amount of deposits in Coop Pank reached EUR 507 million by the end of November, having in a month grown by EUR 12 million.
- The bank earned a net profit of EUR 545 thousand in November.
Commentary by Margus Rink, chairman of the management board of Coop Pank: âThe public offering of bankâs shares and the subscription benefit to the clients were the main drivers of customer growth in November. Secondly, we see that the best benefits of Coop stores loyalty programme, available now to Coop Pank debit card holders from 5 November, bring us new clients from among the holders of Coop loyalty card.â
More detailed quarterly reports of Coop Pank are available at: https://www.cooppank.ee/en/financial-reports
Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. It has 15 branch offices and 24 banking points all over the country. The number of clients using Coop Pank for their daily banking reached 61,900. Coop Pank aims to put the synergy generated by the interaction of retail business and banking to good use and to bring everyday banking services closer to peopleâs homes. The main shareholder of the bank is the domestic retail chain Coop Eesti comprising 340 stores.
Â
Further information:
Kristjan Seema
Head of Marketing and Communication
+372 5505 253
kristjan.seema@cooppank.ee
Attachment
Schibsted ASA (SCHA/SCHB) – Share buyback
Schibsted has on 06 December 2019 purchased 42,000 own A-shares at an average price of NOK 260.0205 per share and 19,000 own B-shares at an average price of NOK 244.8586 on the Oslo Stock Exchange. After these transactions Schibsted owns a total of 2,875,267 own A-shares and 1,135,176 own B-shares.
The transaction is part of the buyback program that Schibsted announced 16 July 2019, stating an ambition to buy back up to 2% of the Companyâs shares.
Accumulated, Schibsted has bought back 1.59% of the shares since the program commenced.
Oslo, 09 December 2019Â
SCHIBSTED ASA
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Transactions of managers and of the persons closely related to the person discharging managerial responsibilities
Coop Pank aktsiaselts hereby declares that the following managers, and / or persons closely related to the person discharging managerial responsibilities, have entered into the following transactions:
| Name of the person that has made the transaction | Relation to the issuer | Security | ISIN code | Content of the transaction | Quantity of securities | Price per security | Transaction value | Time of transaction | Place of transaction |
| Jaanus Vihand | Member of the Supervisory Counsel of Coop Pank AS | Coop Pank share | EE3100007857 | Subscription | 30 000 | 1.15 | 34 500 | 04.12.2019 | Over the counter |
| Jaan Marjundi | Member of the Supervisory Counsel of Coop Pank AS | Coop Pank share | EE3100007857 | Subscription | 20 000 | 1.15 | 23 000 | 04.12.2019 | Over the counter |
| Janek Uiboupin | Member of the Board of Coop Pank AS | Coop Pank share | EE3100007857 | Subscription | 20 000 | 1.15 | 23 000 | 04.12.2019 | Over the counter |
| Oà Lucrativo | Person related to Kerli Lõhmus (Member of the Board of Coop Pank AS) | Coop Pank share | EE3100007857 | Subscription | 20 000 | 1.15 | 23 000 | 04.12.2019 | Over the counter |
| Televool OÃ | Person related to Kerstin Loss (person discharging managerial responsibilities) | Coop Pank share | EE3100007857 | Subscription | 15 000 | 1.15 | 17 250 | 04.12.2019 | Over the counter |
| Helle Luks | Person discharging managerial responsibilities | Coop Pank share | EE3100007857 | Subscription | 11 540 | 1.15 | 13 271 | 04.12.2019 | Over the counter |
| Hans Pajoma | Member of the Board of Coop Pank AS | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Margus Rink | Member of the Board of Coop Pank AS | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Mariann Suik | Person discharging managerial responsibilities | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Roman Provotorov | Member of the Supervisory Counsel of Coop Pank AS | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Martin Kuustik | Person discharging managerial responsibilities | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Raivo Piibor | Person discharging managerial responsibilities | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Rasmus Heinla | Person discharging managerial responsibilities | Coop Pank share | EE3100007857 | Subscription | 10 000 | 1.15 | 11 500 | 04.12.2019 | Over the counter |
| Kristjan Seema | Person discharging managerial responsibilities | Coop Pank share | EE3100007857 | Subscription | 5 000 | 1.15 | 5 750 | 04.12.2019 | Over the counter |
| Sauekliinik OÃ | Person related to Karin Ossipova (person discharging managerial responsibilities) | Coop Pank share | EE3100007857 | Subscription | 5 380 | 1.15 | 6 187 | 04.12.2019 | Over the counter |
Â
A notification obligation derives from the Regulation (EU) No 596/2014 of the European Parliament and of the Council article 19.
Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. It has 15 branch offices and 28 banking points all over the country. The number of clients using Coop Pank for their daily banking has reached 58,300. Coop Pank aims to put the synergy generated by the interaction of retail business and banking to good use and to bring everyday banking services closer to peopleâs homes. The strategic shareholder of the bank is the domestic retail chain Coop Eesti comprising 330 stores.
Â
Kerli Lõhmus
CFO
Phone 6690902
kerli.lohmus@cooppank.ee
www.cooppank.ee
Â
Â
Â
ForFarmers N.V.: Update on share buy-back programme ForFarmers
Lochem, 9 December 2019
Update on share buy-back programme ForFarmers
ForFarmers N.V. (ForFarmers) has repurchased 73,616 shares in the period from 2 December 2019 through 6 December 2019.
The shares were repurchased at an average price of â¬5.67 per share, for a total amount of â¬417,375. These repurchases were made in accordance with the authorisation granted by the ForFarmers Annual General Meeting of Shareholders on 26 April 2019 as part of the share buy-back programme as announced on 3 May 2019.
The total number of shares that has been repurchased to date according to this programme is 2,546,241 shares, for a total amount of â¬16,245,153.
More information about the purchase programme is available on the ForFarmers website www.forfarmersgroup.eu/en.
This press release contains information that qualifies as inside information in the sense of Article 7 paragraph 1 of the EU Market Abuse Regulation.
Note to the editor / For additional information:
Caroline Vogelzang, Director Investor Relations & Communications
T: 0031 573 288 194Â Â M: 0031 6 10 94 91 61
E: caroline.vogelzang@forfarmers.eu
About ForFarmers N.V.
ForFarmers N.V. is an international organisation that offers complete and innovative feed solutions for livestock farming. With its âFor the Future of Farmingâ mission, ForFarmers is committed to the continuity of farming and further sustainalising the agricultural sector.
ForFarmers is the market leader in Europe with annual sales of approximately 10 million tonnes of animal feed. The company is operating in the Netherlands, Germany, Belgium, Poland and the United Kingdom. ForFarmers has approximately 2,700 employees. In 2018, the turnover amounted to over â¬Â 2.4 billion.
ForFarmers N.V. is listed on Euronext Amsterdam.
ForFarmers N.V., P.O. Box 91, 7240 AB Lochem, T: +31 (0)573 28 88 00, F: +31 (0)573 28 88 99,
info@forfarmers.eu, www.forfarmersgroup.eu
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including those relating to ForFarmers legal obligations in terms of capital and liquidity positions in certain specified scenarios. In addition, forward-looking statements, without limitation, may include such phrases as âintends toâ, "expectsâ, âtakes into accountâ, "is aimed atâ, ''plans toâ, "estimated" and words with a similar meaning. These statements pertain to or may affect matters in the future, such as ForFarmers future financial results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties, which may mean that there could be material differences between actual results and performance and expected future results or performances that are implicitly or explicitly included in the forward-looking statements. Factors that may result in variations on the current expectations or may contribute to the same include but are not limited to: developments in legislation, technology, jurisprudence and regulations, share price fluctuations, legal procedures, investigations by regulatory bodies, the competitive landscape and general economic conditions. These and other factors, risks and uncertainties that may affect any forward-looking statements or the actual results of ForFarmers, are discussed in the last published annual report. The forward-looking statements in this press release are only statements as of the date of this document and ForFarmers accepts no obligation or responsibility with respect to any changes made to the forward-looking statements contained in this document, regardless of whether these pertain to new information, future events or otherwise, unless ForFarmers is legally obliged to do so.
MegumaGold Continues to Expand Land Position on Moose River Anticline
Entered Into a Strategic Option Agreement With Genius Metals Inc. on Extension of Touquoy West Exploration Licences
HALIFAX, Nova Scotia, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MegumaGold Corp. (CSE: NSAU, OTC: NSAUF, FWB: 2CM2) (âMegumaGoldâ or the âCompanyâ)Â is pleased to announce that is has entered into an option agreement with Genius Metals Inc. (CSE: GENI) ("Genius") to acquire up to a 100% interest in 6 mineral exploration licences totalling 100 claims (1,620 hectares) directly adjoining the Companyâs Touquoy West licences to the east and St Barbara Ltd.âs licenses to the west (See Figure 1 below).
Figure 1 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99e45978-ac40-4d8f-93e4-2d036d4d19ff
The Genius licences encompass the interpreted Western Extension of the Moose River trend which hosts St Barbara Ltd.âs operating Touqouy Gold Mine, its Beaver Dam and Fifteen Mile
Stream development projects. In combination, these deposits contain current Proven and Probable Mineral Reserves of 1.9 million contained gold ounces. In 2020, the Touquoy Gold Mine is expected to produce 95,000-105,000 ounces of gold at all-in-sustaining-costs between US$630-$670/oz, making it one of the lowest cost producers in the world (Information regarding the Touquoy Gold Mine and the Beaver Dam and Fifteen Mile Stream development projects is taken from a St Barbara Ltd. Corporate Presentation dated November 25, 2019 that is available on that companyâs website).
MegumaGoldâs field work has recently been focused in the Touquoy West Project area (Figure 1) and has been successful in defining large arsenic in soil trends that are locally supported by corresponding elevated gold results (Figure 2). These features are developed along the interpreted west extension of the Moose River anticline that hosts the open pit Touquoy Gold Mine. The Company believes that this structure can be traced along an aeromagnetic trend that extends from the Touquoy Mine area southwesterly across St Barbara Ltd. holdings and then across the Touquoy West holdings. At that point, it appears to continue beyond MegumaGoldâs west property boundary onto the optioned Genius property. The western arsenic and gold in soil trend identified by recent Company work is approximately 2,200 m in strike length at present, has a width ranging between 100 and 700 m, and remains open along strike to the southwest onto the Genius claims (Figure 2).
Figure 2 is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9345d98e-e8f3-4931-b884-767c81e77b79
MegumaGold President Theo Van der Linde stated: "Weâre very pleased to come to this agreement with Genius. The Moose River anticline is a very long anticlinal trend that hosts multiple gold deposits in its eastern and central areas, which has seen very little exploration work in the west. The acquisition of this group of licenses is great real estate for MegumaGold since a large, recently defined arsenic and gold anomaly on the Companyâs adjoining Touquoy West property trends directly onto the newly acquired Genius claims.â Â
Terms of the Agreement
Under the terms of the agreement the Company may earn up to a 70% interest in 6 Genius mineral exploration licences by satisfying the following conditions:
- MegumaGold shall issue to the Genius within ten (10) business days from the Effective Date, an aggregate of 250,000 common shares in the capital of the Company (the âConsideration Sharesâ). The Consideration Shares are subject to a statutory four (4) months and one (1) day hold period. In addition to the statutory hold period, 50% of the Consideration Shares are subject to a contractual one (1) year hold period.
 - Initial 49.9% Earn-In: In order to earn the initial 49.9% interest in the Property, MegumaGold shall, within 18 months from the Effective Date, incur initial exploration work on the Property relating to an initial exploration program made up of ground surveys to pre-drilling targeting work, totalling at least $100,000 (âPhase I Programâ).
 - Additional 20.1% Earn-In: In order to earn an additional 20.1% interest in the Property, MegumaGold shall, within 12 months from the latest date of which the Company satisfies its Initial Earn-In obligations set out above, incur or cause to be incurred, a diamond drilling program on the Property, totalling at least $150,000 (âPhase II Programâ).
 - Upon MegumaGold fully exercising the Option in its entirety to earn 70% of the Property, Genius shall have the option to convert its remaining 30% interest in the Property, into a 2% net smelter royalty (âNSRâ), resulting in MegumaGold owning a 100% interest in the Property, and Genius owning a 2% NSR on the Property. The terms of the NSR shall be defined under standard industry terms and shall be set out in a net smelter royalty agreement to be negotiated between Genius and MegumaGold, which shall include, among other things, a term whereby Meguma will have an option to acquire 50% of the 2% NSR for $1.0 million, leaving Genius with a 1.0% NSR.
Review and Qualified Person
This press release has been reviewed and approved by Regan Isenor, Chief Executive Officer of MegumaGold Corp.; Michael Cullen, P. Geo., of Mercator Geological Services Ltd., an âIndependent Qualified Personâ as defined under National Instrument 43-101, has reviewed and approved references to historic and current exploration information included in this press release.
About MegumaGold Corp.
MegumaGold is a Canadian junior gold exploration company engaged in the business of acquiring, exploring and developing natural resource properties. During 2018, the Company centered its exploration focus on the developing Meguma Supergroup gold play of Nova Scotia. As a result, the Company has assembled a strategically-positioned land position of 107,114 hectares within this promising geological domain.
For more information please contact
Mr. Regan Isenor, Chief Executive Officer
902-233-4381
info@megumagold.com
www.megumagold.com
Forward-Looking Statements
All statements in this presentation, other than statements of historical fact, are "forward-looking information" with respect to MegumaGold within the meaning of applicable securities laws including, without limitation economic estimates and any statements related to estimated mining costs. MegumaGold provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to exploration findings, results and recommendations, as well as those risks and uncertainties identified and reported in MegumaGoldâs public filings under its SEDAR profile at www.sedar.com. Although MegumaGold has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. MegumaGold disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
The Mystery of the Maldives, Unveiled
MALE, Maldives, Dec. 9, 2019 /PRNewswire/ -- Accor, a world-leading, augmented hospitality group with more than 4,900 hotels and residences across 110 countries, is an expert at introducing travelers to new destinations. The Maldives is one of the company's latest favorites. In recent years, Accor has doubled down on its investments in the Maldives, bringing no fewer than five of its brands to the islands. With Raffles, Fairmont, Pullman, Movenpick and Mercure each residing on various atolls, Accor's hotels in the Maldives are welcoming to all guests, whether they seek a more economical mid-level experience or the finest level of luxury.
The Maldives has always seemed a world apart. Fittingly, an otherworldly experience is just what guests find when they reach the ring-shaped coral atolls that comprise the tiny nation of the Maldives. It is a pristine place of untouched natural beauty, quiet solitude and unmatched levels of personal service. The resorts on the Maldives offer spectacular marine adventures, outstanding cuisine and some of the most spiritually resonating spa and wellness experiences in the world.
The islands of the Maldives have a long history of attracting some of the world's most glamorous and famous travelers. Gwyneth & Brad, Prince William & Duchess Kate, Kate Moss, Kate Winslet… seemingly all the Kates that England has to offer, have holidayed in this stunning archipelago dotting the Indian Ocean. The promise of endless vistas and luxurious seclusion has beckoned even the Beckhams to its beaches for a romance-rekindling vacation.
Royalty, film stars and celebrities are blessed with teams of staff and private jets to turn their travel desires into reality. Yet for many people, the Maldives remains a distant dream of a far-flung destination, with a complexity of accommodations and a lack of time and funds to arrange it all.
"Venturing into the unknown is less daunting when a familiar face awaits at the other end," said Becky Powell, travel expert and President of Protravel International. "A trusted and reliable hotel brand will help you feel comfortable even before you've left home. Communicating with hotel staff in advance, and getting advice and support with planning, bookings and transfers, can help set expectations and give you confidence in the quality of care and service you will receive during your stay."
"The Maldives is one of the world's most sought after destinations and our goal is to provide a diverse collection of hotels that allow guests to experience the vibrant and unspoiled marine life of the islands, in the style and manner they feel is most rewarding to them," said Patrick Basset, Accor's Chief Operating Officer, Upper Northeast & Southeast Asia and the Maldives. "Whether it's a champagne breakfast on a private island, or a picnic lunch on a dive boat, the unique resorts of Accor ensure that luxuries and comforts are personally meaningful and effortlessly delivered, while honoring and protecting the mystique of this astonishing part of the world."
Of course, the first step is getting there. Guests typically fly into the Velana International Airport, centrally located in the capital city of Male Hotel representatives greet guests here, before escorting them onward to seaplanes, speedboats or domestic flights. Fairmont Sirru Fen Fushi and Movenpick Resort Kuredhivaru are located about an hour to the north; while Raffles Maldives Meradhoo Resort, Pullman Maldives Maamutaa Resort and Mercure Maldives Kooddoo Resort are all located to the south, about an hour and half from the Malé airport.
For the ultimate in idyllic luxury vacations, guests choose Raffles Maldives Meradhoo Resort. Since 1887, Raffles hotels have enchanted their well-traveled guests with an elegant oasis style and discreet charm. Guests feel pampered and privileged while regaling in signature Raffles indulgences, such as the Long Bar, with its list of vintages to match those reserved in the British Royal cellars, and the lotus-inspired tranquility of the Raffles Spas.
In May 2019, the Raffles resort opened along the southern tip of the Maldives, in the remote and pristine Gaafu Alifu Atoll. The magnificent retreat includes two private islands, one with 21 villas and residences, a Raffles Spa, two beachfront restaurants and a world-class dive center with an on-site marine biologist. A quick boat ride takes guests across the water to its second island, where 16 vast overwater villas reside, along with Yuzu, a sophisticated restaurant serving Nikkei cuisine; the sunset facing Yapa pool bar; and a wildly romantic fire pit dining experience right on the beach.
Together these two private islands offer two distinct experiences, bound together by Raffles' legendary service, including the gentle and intuitive attentions of the Raffles Butlers, exclusive marine butler service, children's butlers and private chefs.
For an experience of more casual luxury with just as much genuine warmth and personal attention, guests choose Fairmont Maldives Sirru Fen Fushi. This luxury leisure resort opened in 2018 on the northern tip of the region, on the island of Sirru Fen Fushi. The only resort on the Shaviyani Atoll, the property overlooks one of the largest natural lagoons in the Maldives.
Fairmont is beloved for its unrivalled experiences and the resort in Maldives is no exception. Some 120 sumptuous villas are dotted around the property, with beach villas, water villas and the utterly unique jungle tented villas. These safari-style accommodations create magical nights with the feeling of sleeping under the stars. By day, guests enjoy the al fresco living areas and outdoor rain showers.
Castaway picnics, dolphin cruises, and sunset sailing are just a few of the diversions here. Yet snorkeling around the Coralarium is one of the property's must-do experiences. An art installation and a home to millions of sea creatures, the Coralarium is designed to raise awareness of coral depletion as well as providing a thriving coral regeneration reef. An on-site manta ray cleaning station offers guests a rare and intimate glimpse of one of the world's most majestic marine creatures, as they swim by in a beautiful display of aquatic symbiosis with smaller sea life.
A stay at any Fairmont hotel is truly unforgettable, not merely for the extraordinary experiences, but in large part due to the thoughtful and engaging colleagues who aim to make each and every stay a cherished and memorable experience.
Just south of the Fairmont, on the Noonu Atoll, Movenpick Resort Kuredhivaru also opened in 2018 and is equally committed to sustainable development and preserving the sensitive environment of the region. The resort employs built-in solar panels, in-house water production and plant desalination to minimize its ecological impact on the environment.
The brand stays true to its culinary heritage, even while thousands of miles from its birthplace in Switzerland. Guests delight in the brand's signature food offerings, including the Movenpick Coffee & Wine Lounge, serving Movenpick coffees, chocolates, ice-creams and wines; and the Movenpick Chocolate Hour, a daily pop-up in the lobby offering guests complimentary chocolate treats, presented in new and interesting ways each day.
The littlest guests are perhaps the biggest fans of the resort, especially taking part in the Movenpick Little Birds Club. Fun and energetic activities keep the kids active and smiling. Watersports, games and sailing cruises can be arranged for the whole family, while babysitting services allow everyone to enjoy a bit of personal time.
Meanwhile, back on the southern area of the Gaafu Alifu Atoll, on the opposite side from Raffles, sits the Pullman Maldives Maamutaa Resort and the Mercure Maldives Kooddoo Resort.
When the goal is a limitless escape, the most recently opened Pullman Madlives Maamutaa is the destination of choice. Surrounded by a lush tropical forest, 122 villas sprawl among 19 hectares of thick mangroves, lush vegetation and a natural lake. Family villas provide ample room to spread out, while two aqua villas feature an incredible experience of 'sleeping with the fishes' - underwater bedrooms feature windows that display a colorful array of coral, fish, and maybe even a visiting shark.
In keeping with the Pullman philosophy of achieving the perfect balance between peak performance and personal wellbeing, the resort boasts one of the most generous all-inclusive programs in the region. Six unique and cosmopolitan dining options include a sunken pool bar, a tapas and cocktail lounge; and a vegan restaurant set amidst an organic garden. A playful food cart makes the rounds of the property throughout the day, offering refreshing sorbets and light snacks for those who prefer to nosh when the mood strikes.
Pullman guests love to stay active, and the resort thrives on sports and games, with nature walks, treasure hunts, a Fit Trail island jogging track and a complete boot-camp Raaveriya Workout that kicks off with calisthenics followed by an invigorating run on the beach and a refreshing swim in the lagoon.
Water sports are a defining factor at Mercure Maldives Kooddoo Resort. Sailing, kayaking, jet skiing, snorkeling, and a world-class diving center are all designed to help guests feel immersed in the ocean experience and the crystal-clear azure waters that surround them.
The Mercure opened in 2017 as Accor's first Maldives property. While it remains the company's most prudent brand in the region with respect to price point, with 43 over water villas and 25 beach villas, there is still a strong sense of splendor here that is simply synonymous with the hospitality culture of the Maldives.
"A memorable getaway in the Maldives is a given, at any price," added Mr. Basset. "Wherever you stay, you are surrounded by spectacular beauty. The sand and sea are perfectly unspoiled, the people are kind and hospitable, and the air and oceans are teeming with life. Once you have the opportunity to experience the Maldives, you will wish to visit the destination again and again."
For more information, rates and reservations, please visit all.accor.com
Media Enquiries:
Joyce Ong, Vice President Communications
Accor – Upper Southeast & Northeast Asia and the Maldives
E: joyce.ong@accor.com
Harry Greig, Communications Manager
Accor – Upper Southeast & Northeast Asia and the Maldives
T: +66-65-510-5290 | E: harry.greig@accor.com
SOURCE Accor
Landore Resources Limited Soil Sampling Program Establishes Significant Anomolous Gold Along Strike from the Bam Gold Project Junior Lake Property
(AIM Ticker: LND.L)
LONDON, Dec. 9, 2019 /CNW/ - Landore Resources Limited (AIM: LND) ("Landore Resources" or "the Company") is pleased to report on the results of the 2019 soil sampling program carried out along strike to the east and west of its BAM Gold Project, Junior Lake Property, Ontario, Canada.
Highlights:
- Landore Resources' geological team completed an extensive exploration campaign during the summer of 2019 which included the establishment of a cut grid, ground geophysics, geology, drilling and soil sampling westwards along strike for approximately 7 kilometres from the existing BAM Gold Project successfully establishing the presence of widespread anomalous gold and indicating multiple gold trends.
- The program has provided drill targets from the western extent of the BAM Gold Resource at 1000E to Juno Lake, a distance of approximately 1,300 metres, and eastwards from 3900E. Elevated gold in soil sampling in these areas supports extending the resource drilling in both directions from the BAM Gold Resource.
- The 2019 soil sampling programme within the highly prospective Felix grid area, 5 kilometres long x 1.2 kilometres wide located to the west of Juno Lake, has identified numerous gold anomalies and trends with similar geology and geophysics to that of the existing BAM Gold Project. The Felix area will require additional infill lines of soil sampling before drilling can commence.
A map titled Junior Lake Property BAM Gold Project Response Ratio Anomalies Au, As, Cu and Gold (Au) Trends, Geology can be viewed on Landore's website www.landore.com.
Commenting on this report, Chief Executive Officer of Landore Resources, Bill Humphries, said:
"The highly successful soil sampling programme completed this summer has established the presence of widespread anomalous gold and multiple gold trends along strike for 7 kilometres to the west of the BAM Gold Project. The programme has identified numerous new drill targets with the potential of being advanced into additional resources ensuring the continued rapid growth of the BAM Gold Project."
2019 SOIL SAMPLING PROGRAMME, JUNIOR LAKE PROPERTY
Landore Resources' geological team completed an extensive exploration campaign during the summer of 2019 which included the establishment of a cut grid, an Electromagnetic (HLEM-MaxMin) VLF and Magnetometric ground geophysics survey, geology, drilling and soil sampling westwards along strike for 7 kilometres from the existing BAM Gold Project successfully establishing the presence of widespread anomalous gold and multiple gold trends.
Justin Johnson (P.Geo, Ontario Canada) Senior Geologist of Panoramic PGMs (Canada) Ltd., was seconded to Landore Resources Canada Inc. for the exploration of the Junior Lake property and was responsible for the implementation, interpretation and reporting of the 2019 soil sampling programme.
Extracts from the 2019 Soil Sampling Programme Report:
"Summary
The Junior Lake property is located approximately 230 kilometres north-northeast of Thunder Bay, ON. The property contains three NI43-101 compliant mineral resources, two of which are predominately nickel (B4-7 and VW) and one which is gold (BAM Gold).
During the summer of 2019 30.1km of grid line was cut and used for geophysical surveys (VLF, MaxMin and ground magnetometer). Geological mapping and soil sampling were conducted between the months of May and November, 2019.
Soil sampling of the B horizon was conducted on the new grid as well as selectively over the pre-established Junior Lake Grid. A total of 1036 samples and 105 control samples were submitted to ALS Global for analysis. Samples were taken at a nominal spacing of 25m on the established lines. Numerous areas were unable to be sampled due to swampy conditions or signs of disturbance from past forestry operations.
The soil sampling program was deemed a successful tool for gold exploration on the property. Numerous anomalous gold trends were noted. Four priority areas were noted which are: 1) Continuation of the BAM Gold trend an additional 1.5 km to the west, 2) Anomalous gold values associated with iron formation between Felix Lake and Boras Lake, 3) Anomalous gold values continuing west towards Juno Lake along the projected metasedimentary sequence of the BAM gold and the possibility of a southwest splay from this trend passing just south of Juno Lake, and 4) Line 4100E, located 1.1 km east of the defined BAM Gold deposit and 100m east of five exploration diamond drill holes, completed in 2018, that intersected elevated gold values.
Introduction:
A large grid was cut on the Junior Lake property during the summer of 2019 and used for multiple exploration surveys. The grid roughly spanned 5km x 1.2km and was used as the basis for the soil sampling program. A limited number of samples were also collected over the already established Junior Lake grid.
The soil sampling program collected a total of 1141 samples, including 115 reference samples. The samples were collected from the B horizon at a nominal distance of 25m along the grid lines using a Dutch auger.
The area was extensively logged ~20 years ago. As a result areas with obviously disturbed soil were not sampled. In addition, areas with thick organics or A horizons >2m, the limit of the soil auger, were not sampled.
In order to help exploration three lines were conducted over areas of known mineralization of the BAM deposit. From these test lines a geochemical profile of the BAM deposit was determined."
"2019 Soil Sampling:
Soil sampling was conducted on two established grids. The Felix Lake grid consists of northeast-southwest orientated lines spaced 100 m to 300m apart and was sampled in its entirety. The Junior Lake grid consists of north-south orientated lines spaced 100m apart and was selectively sampled. Samples were collected every 25m using a 4 cm Dutch auger and placed in clean, brown paper bags specifically designed for this type of material. Samples had their depth of collection noted as well as a general description of the sample itself (see Appendix II). In areas of poor soil development composite samples were taken using multiple holes. Areas where a sample was not able to be taken due to either deep overburden or disturbed soil had the reason noted. Once collected samples were dried in camp before shipment to the laboratory.
Duplicate samples were taken (4% of samples) and silica blanks were inserted (4% of samples). Replicate samples were taken on five lines. The replicate samples consisted of four samples taken on an approximately 1 m x 1 m grid at the end of a survey line.
A total of 1141 samples were submitted to ALS Global of Vancouver for analysis. At ALS Global the samples were analyzed for low level gold in soils and sediments. The analytical package used was 'Prep-41, Au Me-ST 43' which involves drying at <60oC and sieving to -180 micron followed by aqua regia digestion and ICP-MS finish for analysis of gold and 42 other elements. The samples submitted consisted of 1036 individual soils, 45 duplicate soils, 15 replicate samples and 45 silica blanks.
To help identify the geochemical signature of the gold mineralization three control lines were conducted in areas of known mineralization, as proven by past drilling.
QAQC:
The duplicate samples taken correspond well. The majority of elements have 70-90% within +/-20% of the duplicate values, that increases to >90% of the values when the range is expanded to +/-30%. The outliers may in part be attributed to the sample sites. Numerous locations had thin B horizons which resulted in composite samples being taken. It is likely this contributed to the variation in duplicates.
The replicate samples were taken at five separate locations and consist of four samples on an approximate one meter by one meter square. In three of the replicate sets taken all samples were within 20%. For two of the replicate sets one of the four samples was >20%. This was considered within acceptable limits and the data set was used in its entirety.
Soil Sampling Results:
To remove anomalous samples, they were screened based on their description. Samples described as organic rich, black or grey in colour or clay were considered suspect and may not be representative of the B horizon. The remaining samples were used for the calculation the background value of each element. The background value is the average of the lower 25% quartile, listed in Table 2.
Table 2: Select elements' calculated background values.
| Element | Au | Ag | As | Cu | Ni |
| Background Value | 0.299 ppb | 0.013 ppm | 1.19 ppm | 4.35 ppm | 6.43 ppm |
The response ratios (RR) were calculated for all elements by taking the background value and dividing it into the analytical value. This was also done for the suspect samples. RRs are rounded and values of >=5 considered anomalous.
A correlation matrix was also generated for the samples taken. Gold (Au) showed only a very weak correlation with cobalt, chromium, magnesium and sodium. As a result it was determined that use of the correlation matrix was not helpful at this time.
An examination of the gold RR showed there were 147 samples with anomalous values (RR>=5). Of these samples 25 had values of 10-30 while 15 had RR >30. Maps showing the anomalous sites for Au, As, Ag, Cu, Au +As +Cu are in Appendix I. In order to correlate anomalies across lines the regional fabric of the area was used. Within the area there is a general fabric that strikes 105-115o, this is highlighted by the recently completed geophysics (VLF, MaxMin). The geophysics highlights formation sulphide zones within the area and is used as both marker horizons and to illustrate the fabric within an area.
It is important to note that there are cross cutting structures within the area. These structures may play an important role in the gold mineralization, acting both as pathways and aiding in concentrating the auriferous fluids. As such they will require additional investigation and follow-up in the future.
Appendix I contains a map illustrating the trend of gold within the soil samples taken. In order to help prioritize them, a signature for the gold mineralization of the BAM deposit was established. To do this examination of the three control lines (L1000E, L2700E and L3400E) through the defined deposit was conducted. Examination of the control lines yielded mixed results with the combination of Au+As+Cu being considered most useful.
L1000E
L1000E covers the historic BAM occurrence (located on the western limit of the defined BAM Gold deposit), values up to 11gpt/Au at surface, as well as the BAM Gold zone defined by drilling. The soil geochemistry response near the surface occurrence shows a dramatic arsenic spike (RR 11-54) as well as copper (RR 7-11) and anomalous gold (RR 5-6) and a broader silver (RR 4-5) response.
Additional Au and Au+As+Cu anomalies are located along the southern portion of the sampled line. Sparse previous drilling has been conducted for nickel in this area in the past.
L2700E
L2700E covers the drilled portion of the BAM deposit with no surface exposure. Due to the disturbed nature of the soil the area overlaying the projected gold zone could not be sampled. Samples analyzed from near the projection contained no anomalous values.
L3400E
L3400E is located 100m to the west of an established drill line. The projected gold zone correlates with anomalous gold (RR 8, 10), silver (RR 4, 5) and copper (RR 3, 5) anomalies. A 100m silver anomaly is located 100m south of the projected BAM gold zone but does not have any other correlating signatures.
To determine significant anomalies several elements with RR>=5 were looked at. Au, Ag, As, Cu and Au+As+Cu (see Appendix I) were looked at. Locations with coincident Au+As+Cu, and to a lesser extent Ag, anomalies were considered to have the same characteristics as the BAM occurrence and examined in detail.
Thirty-one sites were found with coincident Au+As+Cu anomalies and are listed in Table 3.
Table 3: Samples containing anomalous Au +As +Cu. Location and RR values given. A) Felix Lake Grid. B) Junior Lake Grid.
A) Felix Lake Grid
| Sample | Line | Station | Response Ratio | Notes
| |||
| Au | As | Cu | Ag | ||||
| A0058622 | L5700W | S200 | 5 | 11 | 77 | 8 | Location has anomalous Au in sample 100m along strike to the SE, limited strike length |
| A0058707 | L5000W | S360 | 29 | 12 | 23 | 10 | Location along southern margin of a swamp also along edge of interpreted iron formation may represent edge of anomaly. May have additional strike length |
| A0058817 | L4300W | S275 | 7 | 11 | 12 | 3 | Anomalous Au +As values in sample 25m north. Interpreted to be part of a continuous trend <=800m in length |
| A0058908 | L3700W | N75 | 6 | 125 | 15 | 17 | Located ~50m N of the projected metasediments of the BAM Gold deposit, within a larger Cu anomaly that extends 25m south and 125m north on L3500W. Parallel Au trend 25m north |
| A0058951 | L3500W | N50 | 7 | 5 | 28 | 6 | |
| A0059060 | L2800W | N200 | 13 | 6 | 10 | 4 | Additional anomalous Au +As values 25m N, swamp located ~30m prevented further sampling to north. Part of 900m Au trend extending to W. Alternative trend can connect to samples A0058909 & A0058951 |
| A0059103 | L2500W | N775 | 8 | 286 | 41 | 10 | Additional anomalous results 25m N (Cu), 25m S (As +Cu), 50m S (Au) and along strike 200m SE of Au and Cu |
| A0059277 | L1700W | N500 | 11 | 6 | 9 | 1 | Located ~150m N of the interpreted BAM Gold metasedimentary sequence. Cu anomaly continues 75m S and As anomaly continues 25m S, additional Cu anomalies 200m SE along strike |
| A0059316 | L1500W | N400 | 12 | 11 | 11 | 2 | Located ~50m N of interpreted BAM Gold metasedimentary sequence. Cu anomalies continue 25m S and 100m N. Interpreted to be part of ~1.3km long trend parallel to BAM sequence |
| A0058531 | L1000W | N25 | 5 | 10 | 13 | 4 | Samples within swampy region with sparse samples. Nearest samples contain anomalous Cu (150N), As (175N) and Cu +As (50N). Due to sparse samples correlation is difficult, possible extension of sample trend A0059434 |
| A0058530 | L1000W | N75 | 5 | 7 | 17 | 4 | |
| A0059437 | L100W | N550 | 5 | 8 | 9 | 1 | Sample within a large N-S-E Cu anomaly. Location is ~150m south of the BAM Gold metasedimentary package |
| A0059434 | L100W | N300 | 21 | 29 | 7 | 2 | Location north of historic drilling in area of disturbed soils. Located 100m W of A059413 |
B) Junior Lake Grid
| Sample | Line | Station | Response Ratio | Notes | |||
| Au | As | Cu | Ag | ||||
| A0059416 | L000 | N375 | 7 | 14 | 9 | 2 | Locations are part of a large zone of anomalous Cu, As and Au values surrounding an E-W swampy area south of the BAM Gold trend. Samples part of 'Y' shaped trend west of BAM Gold drilling. May represent Au bearing splays from main structure |
| A0059413 | L000 | N300 | 6 | 12 | 8 | 3 | |
| A0059397 | L100E | N450 | 10 | 18 | 11 | 1 | |
| A0059395 | L100E | N375 | 5 | 16 | 28 | 6 | |
| A0059375 | L200E | N525 | 5 | 9 | 7 | 1 | |
| A0059356 | L300E | N510 | 12 | 67 | 45 | 3 | |
| A0059358 | L300E | N550 | 16 | 7 | 6 | 4 | |
| A0059357 | L300E | N525 | 6 | 12 | 8 | 2 | |
| A0059353 | L300E | N325 | 5 | 53 | 9 | 4 | |
| A0059354 | L300E | N350 | 5 | 9 | 7 | 2 | |
| A0059460 | L400E | N400 | 6 | 24 | 12 | 3 | |
| A0059466 | L500E | N500 | 5 | 20 | 7 | 1 | |
| A0059471 | L500E | N600 | 9 | 140 | 96 | 7 | Locations above and north of the BAM Gold metasedimentary sequence. Connects to anomalous As and Au to the E and to the BAM occurrence |
| A0059473 | L500E | N650 | 53 | 25 | 7 | 2 | |
| A0059606 | L4100E | S200 | 147 | 44 | 80 | 40 | Locations are within 200m swampy area. Additional anomalous Au +Cu located at the southern swamp boundary |
| A0059611 | L4100E | S300 | 7 | 10 | 10 | 5 | |
| A0059621 | L4100E | S600 | 70 | 6 | 5 | 4 | Samples are within the middle of a ~300m wide series of Cu, As +Cu and Au +As anomalous values |
| A0059620 | L4100E | S550 | 7 | 8 | 18 | 5 | |
Interpretation:
Gold appears to respond well to the sampling program conducted. It is possible to link together anomaly trends across 100s of meters. It is important to not just rely on the intensity of the RR but to also use a multi-element classification. This is highlighted when the BAM occurrence is examined where multiple gram surface samples generate an Au RR of 5-6 in the immediate samples. This criteria is not meant to exclude single element Au anomalies.
Through use of the soil data the BAM Gold trend is extended 1.5km to the west. Additional anomalies continue for 1.5km and may be proven to be connected. Multiple additional areas of interest have also been generated and may correlate to addition gold horizons.
The response of nickel to the use of soil sampling was also examined. A total of 37 samples had RR >= 5 for Ni. Of these samples 90% of them correlate with anomalies from the 2019 VLF and MaxMin surveys and are interpreted to be a result of sedimentary sulphide package used as a marker horizon in the footwall of the BAM Gold deposit. In addition the Ni anomalies are single sample responses and have limited strike. As such, soil sampling has limited use for generating nickel targets and more traditional ground or airborne EM should be used.
Conclusions and Recommendations:
The 2019 soil sampling program was successful in generating several anomalies of interest. Gold is shown to respond well to the low cost survey and has strong potential for future exploration
Recommendations:
- Additional infill lines should be conducted in areas of interest. These lines can be done quickly via GPS and do not require a cut line. Line spacing should be reduced to 100m spaced lines with samples every 25m. The length of the infill line should extend a minimum of 100m above and below the interpreted anomaly.
- Intensive prospecting to be conducted along anomalous gold trends. Previous work has indicated that unassuming, weakly sheared surface samples can return significant gold values. Due to this sampling of all outcrops, where they occur, needs to be conducted in high priority areas. Ideally samples perpendicular to the trend should be spaced 10m while sampling along the strike of the anomaly <50m.
- Property scale exploration to be done using 500m spaced lines across areas of interest both east and west.
- Test lines should be done over the Lamaune Gold occurrence to determine its characteristics.
From the soil sampling program there are four areas identified as priority targets:
- Gold anomaly trend west of Juno Lake, adjacent to the interpreted BAM Gold metasedimentary sequence. The presence of anomalous gold values along this trend gives additional strength to the continuation of gold mineralization along this horizon.
- Follow up on the anomalous trends between Felix Lake and Boras Lake associated with the iron formations. Unfortunately terrain may prove to be a problem as much of the area has thick overburden.
- Follow up on the gold trend westwards from line 1000E, towards Juno Lake along the projected metasedimentary sequence of the BAM Gold deposit and coincident gold anomalies. The possibility of a southwest auriferous splay occurring and passing just south of Juno Lake needs to be evaluated.
- L4100E, located 1.1 km east of the defined BAM Gold deposit, contains numerous anomalies including the highest Au RR (147) of the survey. Past work in the area is limited to five exploration diamond drill holes conducted in 2018 and located 100m east. These exploration diamond drill holes intersected elevated gold values and are project along strike to occur."
End of extracts from the 2019 Soil Sampling Programme Report
A copy of the full Report on 2019 Soils Sampling Programme, Junior Lake Property can be viewed on Landore's website www.landore.com.
ONTARIO GEOLOGICAL REPORT
Open File 6223, 43p.
In 2008 the Ontario Geological Survey published a report by P. J, Barnett on the 'Till signature of the Caribou Lake greenstone belt area, Armstrong, Ontario.'
The Abstract reports:
"Surficial sediments in the area north of Lake Nipigon can be successfully used for mineral exploration and to determine the natural distribution of elements in the environment. Till, the ideal sediment for sampling, is wide spread and commonly reflects local bedrock conditions in the area. Over 130 samples were collected for geochemical analysis and 92 samples were collected for heavy mineral analysis over an area of 5000 km2 centred on the Caribou Lake greenstone belt. The Caribou Lake greenstone belt ranges from 3 to 17 km wide and extends for nearly 100 km where it merges with the Onaman-Tashota greenstone belt. It consists primarily of massive to pillowed basalts, iron formation and komatiite with minor amounts of conglomerate. It is being explored for gold, molybdenum, copper-nickel-platinum group elements (PGE) and rare-element pegmatites."
The Junior Lake Project is situated in the eastern 32 kilometres of the above-surveyed Caribou Lake Greenstone belt. Till samples taken by the Ontario Geological Survey that are within the Junior Lake Project area are recorded to contain high levels of gold and other metals, supporting Landore Resources' findings from its 2019 soil sampling program and establishes the Junior Project to be a prime gold address.
BAM Gold Deposit:
The BAM Gold Deposit, discovered in December 2015, is located in the south-central area of the Junior Lake property and is interpreted as an Archean-aged mesothermal gold deposit in which gold mineralisation is hosted by sheared and altered rocks of the Grassy Pond (Gabbro) Sill and the BAM Sequence. The host rock units strike in an east-southeast direction (average of azimuth 105°) and dip steeply to moderately to the south at 70 to 80 degrees. The gold mineralisation is interpreted to reside within a series of tabular shaped zones that are oriented in a roughly en-echelon configuration and are generally parallel to the overall strike of the host rock units.
BAM Gold Resource and PEA:
A Technical Report and Preliminary Economic Assessment ("PEA") of the BAM Gold Project was reported 20th February 2019. The report is in compliance with the requirements of the Canadian National Instruments 43-101 Standards of Disclosure for Mineral Projects ("NI 43-101").
BAM Gold Resource and PEA Update:
Cube Consulting Pty Ltd ("Cube") has been engaged by Landore Resources Canada Inc. ("Landore") to complete an 'in house' update the BAM Gold Resource to include the 2019 drilling campaign.
The proposed update of the PEA and preparation of an Independent Technical Report on the BAM Gold Project has been deferred until additional resource drilling has been completed on the new targets identified by the 2019 soil sampling program.
The Junior Lake Property:
The Junior Lake Property, 100% owned by Landore Resources, together with the contiguous Lamaune Iron property (90.2% owned) (jointly the "Junior Lake Property"), consisting of 30,507 hectares, is located in the province of Ontario, Canada, approximately 235 kilometres north-northeast of Thunder Bay and is host to: The BAM Gold Deposit; the B4-7 Nickel-copper-cobalt-Platinum-Palladium-gold Deposit; the VW Nickel-Copper-cobalt Deposit; Lamaune Gold Prospect and numerous other precious and base metal occurrences.
A highly prospective Archean greenstone belt traverses the Junior Lake Property from east to west for approximately 31 kilometres. The greenstone belt ranges from 0.5 to 1.5 kilometres wide and contains all of Landore Resources' stated mineral resources and prospects. However, the greater proportion of this belt remains unexplored.
Michele Tuomi, (P.Geo., BSc. Geology), Director/VP Exploration of Landore Resources Canada Inc. and a Qualified Person as defined in the Canadian National Instrument 43-101 and the AIM Rules for Companies, has reviewed and verified all scientific or technical mining disclosure contained in this announcement.
About Landore Resources
Landore Resources is an exploration company that seeks to grow shareholder value through the acquisition, exploration and development of precious and base metal projects in eastern Canada. The Company is primarily focused on the development of the Junior Lake Project. Landore Resources has mineral rights to 5 properties in eastern Canada. The Company is headquartered in Guernsey, with an exploration office located in Thunder Bay, Ontario, Canada.
This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No 596/2014.
SOURCE Landore Resources Canada Inc.
U.S. Gold Corp. Announces Formation of Advisory Board
ELKO, Nevada, Dec. 9, 2019 /PRNewswire/ -- U.S. Gold Corp. (NASDAQ: USAU) (the "Company"), a gold exploration and development company, is pleased to announce that Mr. Ewan Downie and Mr. Mario Stifano have joined its newly established Advisory Board.
Mr. Downie has over 25 years' experience in the exploration and mining industry and is the current President, Chief Executive Officer, and Director at Premier Gold Mines Ltd. (TSX: PG) and Chairman of the Board at Wolfden Resources Corp. (TSXV: WLF).
Mr. Stifano CPA, CA is a senior executive and proven leader with strong capital markets experience, having helped raise over $650 million in cumulative financings in multiple industries, including natural resources, technology, and finance.
Edward Karr, President and Chief Executive Officer of U.S. Gold Corp., stated, "All of the U.S. Gold Corp. team is pleased to welcome Ewan Downie and Mario Stifano to our newly established Advisory Board. Both Ewan and Mario are proven industry leaders with tremendous experience and contacts and became shareholders of the Company with our acquisition of Orevada Metals, Inc. We look forward to their future contributions, guidance, and strategic input."
Mr. Ewan Downie commented, "U.S. Gold Corp. has assembled an impressive portfolio of exploration projects in Nevada, one of the world's most prolific mining jurisdictions. The Company has high-potential projects on two of the State's major gold trends. Both the Carlin and Cortez trends hold tremendous potential, and I am thrilled to be able to add my input and experience to assist in advancing the Keystone and Maggie Creek exploration projects."
Mr. Mario Stifano added, "As an existing shareholder of U.S. Gold Corp., I am enthusiastic about the exploration projects at the Company and I look forward to using my industry experience and contacts to add shareholder value. Quite simply, I believe that Maggie Creek and Keystone are two of the best Nevada exploration projects I have seen, and I look forward to being part of the team."
About U.S. Gold Corp.
U.S. Gold Corp. is a publicly traded U.S. focused gold exploration and development company that has a portfolio of development and exploration properties. Copper King is located in Southeast Wyoming and has a Preliminary Economic Assessment (PEA) technical report that was completed by Mine Development Associates. Keystone and Maggie Creek are exploration properties on the Cortez and Carlin trends in Nevada. For more information about U.S. Gold Corp., please visit www.usgoldcorp.gold.
Forward-looking and cautionary statements
Forward-looking statements in this press release and all other statements that are not historical facts are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks arising from: changes in the price of gold and mining industry cost inputs, environmental and regulatory risks, risks faced by junior companies generally engaged in exploration activities, and other factors described in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
INVESTOR CONTACT:
U.S. Gold Corp. Investor Relations:
+1-800-557-4550
ir@usgoldcorp.gold
www.usgoldcorp.gold
View original content:http://www.prnewswire.com/news-releases/us-gold-corp-announces-formation-of-advisory-board-300970964.html
SOURCE U.S. Gold Corp.
